Pharmaceuticals

Welcome to the first edition of the IIR Movers & Shakers report for Pharma & Biotech. Each month, we will be looking at those stocks that experience significant share...

Can you do well by doing good?"As always, Cipla will follow a compassionate and humanitarian approach to healthcare that goes beyond the pursuit of profit. Access to...

The US tax year is ruled off at the end of December. Typically, there is tax loss selling in US stocks in the lead up to the end of the year, followed by a relief to...

If anyone had a good time during the COVID-19 pandemic, it was the healthcare sector. It was its time to shine. Investors were flocking to the door.  The companies...

In the final part of this collection, we turn our attention to some of the types of assets our four contributors are using to construct portfolios or to advise their...

Astrology followers would know that January is the time for horoscopes, and for market experts to give their view on sharemarket returns for the next 12 months. The...

When receiving my jab last month (thank you nurses at RBWH in Brisbane for your excellent care!) I couldn’t help wondering how much all these vaccines were costing....

The week kicked off with Wesfarmers (ASX:WES) making a $687 million non-binding, indicative offer to acquire Australian Pharmaceutical Industries (ASX:API) at $1.38...

A look at the performance of the pharmaceutical and biotech sector over the month of April, along with companies in the IIR Pharma & Biotech Index that are trading at...

The IIR Pharma & Biotech Index increased slightly in March, up 1.3%. The index has performed strongly since the lows resulting from the pandemic, up 67.4% over the...